Navigation Links
UCLA study assesses cost-effectiveness of Hepatitis B drugs

Researchers at UCLA and the Veterans Affairs Greater Los Angeles Healthcare System conducted the largest and most comprehensive study in comparing the cost-effectiveness of current modern drugs for treating hepatitis B -- a disease affecting 350 million worldwide.

Published in the May 17 Annals of Internal Medicine, the study may help physicians worldwide in making treatment decisions. Researchers note that a degree of uncertainly exists on how to best initiate hepatitis B treatment due to a constant influx of newer, more expensive drugs that all have varying risks and benefits.

"We need to develop a more calculated approach and establish guidelines for the most cost-effective treatment," said Dr. Fasiha Kanwal, first author and research fellow, Division of Digestive Diseases, David Geffen School of Medicine at UCLA and Veterans Affairs Greater Los Angeles Healthcare System.

Researchers performed an economic analysis comparing the cost-effectiveness of five competing drug treatment strategies for chronic hepatitis B: 1) No treatment at all 2) Interferon alone 3) Lamivudine alone 4) Adefovir alone 5) Beginning therapy with lamivudine, but changing to adefovir if viral resistance is encountered.

Investigators found that the newest drug therapy -- adefovir ?was not cost-effective when taken alone. However, adefovir was very cost-effective when reserved as a second-line agent in people who develop viral resistance for lamivudine ?a therapy that has been available for over 15 years.

The study notes that interferon ?the oldest of all available therapies -- may still be preferred in health care systems with limited resources and is especially cost-effective with "e-antigen negative" patients, which is a more serious type of hepatitis B.

"We found that the newer, more 'sexy' drugs are too expensive and better to use only after other first line therapies have failed," said Dr. Brennan M. R. Spiegel, study author and co-director, Center for the Study of Digestive Healthcare Quality and Outcomes and assistant professor of medicine, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System. "The combined treatment strategy of lamivudine and adefovir is also a very viable option. This is part of a trend that we're seeing in other areas of medicine as well ?to use "hybrid" treatments that reserve expensive yet effective drugs for specific patients who have shown no success with other treatments."

Spiegel notes that the general cost-effectiveness standard accepted by society and many insurers for treating a chronic condition like hepatitis B is roughly $50,000 or less per quality-adjusted life-year gained, which is a standard measure used in assessing the outcome of health care procedures or services.

According to Kanwal, the study showed that only two strategies fell well within this accepted standard: Interferon cost an incremental $6,337 to gain an additional quality-adjusted life-year, compared to receiving no treatment at all. Compared with interferon, the hybrid strategy of lamivudine and adefovir cost an incremental $8,446 per quality-adjusted life-year.

In comparison, treatment with adefovir alone cost over $90,000 for each quality-adjusted life-year gained for patients with the e-antigen negative hepatitis B and would not be considered cost-effective according to researchers.

The comprehensive economic model adjusted for various patient scenarios including viral resistance, development of cirrhosis and other factors affecting treatment. Health costs included physician visits, diagnostic tests and complications of chronic liver disease.

Investigators based the model on average 40-year old patients with the most common type of chronic hepatitis B -- with elevated liver enzymes but no liver cirrhosis. Investigators also took into consideration the two types of hepatitis B -- either e- antigen positive or e-antigen negative -- which require different treatment approaches.

Hepatitis B is the most common serious liver infection in the world. The virus attacks liver cells and chronic hepatitis B disease can lead to liver failure, cirrhosis or cancer of the liver. About 90 percent of healthy adults who are infected with Hepatitis B recover with no problems, but 10 percent develop chronic disease. In children who have been infected, 60 percent develop chronic disease.

Other authors include Dr. Ian M. Gralnek, MSHS, Dr. Gareth S. Dulai, MSHS, and Mary Farid, Division of Gastroenterology, VA Greater Los Angeles HealthCare System and Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Center for the Study of Digestive Healthcare Quality and Outcomes, Los Angeles, California; and Dr. Paul Martin, Mount Sinai School of Medicine, New York, New York.


'"/>

Source:University of California - Los Angeles


Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... A recent survey conducted by the ... difficult to control weed in 12 categories of broadleaf crops, fruits and vegetables, while ... across the U.S. and Canada participated in the 2016 survey, the second conducted by ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider of circulating tumor ... circulating tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on May ... Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. ...
(Date:5/23/2017)... ... 23, 2017 , ... Customers often prefer PLC and ... again. METTLER TOLEDO has released two new videos that show how they have ... the ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a genetically ... error process by finding the right antidepressant faster. CNSDose speeds recovery and ... through a personalized approach to treatment. , A peer-reviewed and published, ...
Breaking Biology Technology: